Star Equity Holdings, Inc.
Star Equity Holdings, Inc.
Acquisition Adds Established Enterprise Client Relationships, Experienced U.S. Sales Leadership, and Back-Office Synergies
Source
From GlobeNewswire
20 releases originally issued via GlobeNewswire. The issuing organizations are responsible for their content.
Pacific Biosciences Of California, Inc.
PacBio Announces Third Quarter 2026 Financial Results
National Healthcare Properties, Inc.
National Healthcare Properties Reports Third Quarter 2026 Results
SHOP Same Store Cash NOI increased 13.6% year-over-year —
Carriage Services Inc
CARRIAGE SERVICES INC
Carriage Services Announces Third Quarter 2026 Results, Updates 2026 Guidance
Cytek Biosciences, Inc.
Cytek Biosciences Reports Third Quarter 2026 Financial Results
reAlpha Tech Corp.
reAlpha Tech Corp. Announces Pricing of $1.75 Million Public Offering
Jasper Therapeutics, Inc.
Jasper Therapeutics Announces 1-for-30 Reverse Stock Split
Aprea Therapeutics, Inc.
Aprea Therapeutics Announces Third Quarter 2026 Financial Results
Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026)…
Riot Platforms, Inc.
Riot Platforms Reports Third Quarter 2026 Financial Results and Strategic Highlights
Executed a 15-year, 910 critical IT MW triple-net powered land lease with a leading Frontier AI Lab at Corsicana, representing approximately $28…
Geron Corp
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Achieved $60.1 million in RYTELO® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026
SLR Investment Corp.
SLR Investment Corp. Announces Quarter Ended September 30, 2026 Financial Results
Net Investment Income of $0.33 Per Share for Q3 2026;
InnovAge Holding Corp.
INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE
FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026
Neutron Holdings, Inc.
Lime Announces Third Quarter 2026 Financial Results
Record Third Quarter Revenue of $361 Million, Up 20% YoY
Teva Pharmaceutical Industries Ltd
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION OF BXCL-501
Xometry, Inc.
Xometry Reports Record Third Quarter 2026 Results
Q3 revenue increased 40% year-over-year to a record $252 million, driven by robust marketplace growth.